Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.55 USD | +1.19% | -1.92% | -39.43% |
Apr. 26 | UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating | MT |
Apr. 25 | Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.43% | 564M | |
+0.94% | 42.86B | |
+12.31% | 42.74B | |
+44.30% | 41.36B | |
-6.20% | 27.68B | |
+6.45% | 25.15B | |
-23.64% | 18.63B | |
+28.91% | 12.37B | |
-3.00% | 11.92B | |
+7.09% | 11.21B |
- Stock Market
- Equities
- CVAC Stock
- News CureVac N.V.
- CureVac, GSK's Seasonal Flu Shot Shows Efficacy in Phase 1/2 Study